Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sanofi (NYSE: SNY).

Full DD Report for SNY

You must become a subscriber to view this report.


Recent News from (NYSE: SNY)

Berkshire Hathaway: Are Warren Buffett & Co. Losing Their Midas Touch?
Introduction Last week, we had an interesting discussion on our chat room regarding the high level of cash, about $103.64B (or 34.6% of the liquid-invested portfolio), that Berkshire Hathaway ( BRK.A )( BRK.B ) maintain on its balance sheet. It started with a question by one of our subsc...
Source: SeekingAlpha
Date: December, 10 2018 07:37
Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D Candidates
There are two criticisms you’ll never read about Alnylam ( ALNY ) – that management is insufficiently promotional of the company, and that it doesn’t have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursd...
Source: SeekingAlpha
Date: December, 08 2018 00:23
Altimmune: Suppressed, Immature, Or Dormant?
2018 has been a volatile year for Altimmune ( ALT ) from start to finish. The company experienced mixed results in clinical trials as well as changes management positions. Unfortunately, the share price has taken the brunt of the losses and has gained little from the wins. After a reverse spli...
Source: SeekingAlpha
Date: December, 05 2018 15:22
41 'Safer' Dividend Healthcare Pre-December WallStars From Dividend Dogcatcher
Source: YCharts Actionable Conclusions (1-10): Brokers Forecast Ten High Yield Top Healthcare 'Safer' Dividend Stocks to Net 12.6% to 26.75% Gains To November 2019 Four of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the t...
Source: SeekingAlpha
Date: December, 03 2018 13:45
Cancer Research Highlight: ImmunoGen's Heme Program Rumbles Under The Surface
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you pay attention at all to...
Source: SeekingAlpha
Date: December, 03 2018 08:00
Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November
Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. ...
Source: SeekingAlpha
Date: November, 30 2018 11:58
Ad Com January 17 for Sanofi's diabetes med sotagliflozin
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Thursday, January 17, 2019, to review and discuss Sanofi's (NYSE: SNY ) marketing application seeking approval for Zynquista (sotagliflozin) as an adjunct to insulin to improve glycemic control in adults with type...
Source: SeekingAlpha
Date: November, 29 2018 09:00
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
PARIS and TARRYTOWN, N.Y. , Nov. 7, 2018 /PRNewswire/ --  The New England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met its primary endpoint, showing that Praluent ® (alirocumab) Injec...
Source: PR Newswire
Date: November, 07 2018 17:00
First Eagle Global Value Team Quarterly Commentary Q3 2018
Read more ...
Source: SeekingAlpha
Date: November, 07 2018 02:15
Hoth Therapeutics IPO: Small Company Targeting A Large Market
Developing treatments of eczema, which creates an economic burden estimated to be $5.3 billion, Hoth Therapeutics (HOTH) is targeting a large market. In addition, with other competitors having enterprise value of more than $300 million, HOTH seems undervalued with an enterprise value of $72.64...
Source: SeekingAlpha
Date: November, 06 2018 14:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1044.1544.1744.3843.511,198,132
2018-12-0743.7243.4844.0043.355826,951
2018-12-0643.4443.7143.8242.661,308,064
2018-12-0445.1944.1445.3644.001,520,311
2018-12-0344.3944.5544.6344.221,133,029

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-105,60123,40523.9308Cover
2018-12-0710,13323,19343.6899Short
2018-12-0618,86839,66247.5720Short
2018-12-046,01929,27120.5630Cover
2018-12-0318,36240,16445.7176Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNY.


About Sanofi (NYSE: SNY)

Logo for Sanofi (NYSE: SNY)

Not available

 

Contact Information

 

 

Current Management

  • JeanFrancois Dehecq / CEO
  • Hanspeter Spek / COO
  • Pierre Lepienne / Secretary

Current Share Structure

     


    Recent Filings from (NYSE: SNY)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: September, 05 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: July, 31 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: July, 31 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: July, 26 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: June, 29 2018
    An annual report of employee stock purchase savings and similar plans
    Filing Type: 11-KFiling Source: edgar
    Filing Date: June, 29 2018
    An annual report of employee stock purchase savings and similar plans
    Filing Type: 11-KFiling Source: edgar
    Filing Date: June, 29 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: June, 28 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: June, 20 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: June, 19 2018

     

     


    Daily Technical Chart for (NYSE: SNY)

    Daily Technical Chart for (NYSE: SNY)


    Stay tuned for daily updates and more on (NYSE: SNY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NYSE: SNY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SNY and does not buy, sell, or trade any shares of SNY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/